Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across Canadavi, in federal plans like Non-Insured Health ...
In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S.
Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...
Abbott's Libre Assist will help individuals with diabetes better understand how their food choices may affect their glucose ...
Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers ...
Zacks Investment Research on MSN
Is it the right time to add Insulet stock to your portfolio?
Insulet PODD is well-poised to grow in the coming quarters due to the strength of its Omnipod 5 platform. The company is strongly executing against its long-term priorities to drive penetration, ...
Santa Cruz Sentinel on MSN
Santa Cruz County Fair accepting ideas for 2026 theme
The fair is running its annual theme contest where entrants are asked to submit a clever phrase that will appear in all of ...
The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties.
Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
Raffles London at the OWO has launched a 'high focus, high touch' training regime delivered by an array of elite performance ...
Save for later Page saved! You can go back to this later in your Diabetes and Me Close ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback